Picture Fairtec GmbH Worldwide Event Solutions 650x65px
Document › Details

Biotest AG. (9/9/14). "Press Release: Biotest Completes Recruitment in Phase IIb Study (TREAT 2b) of Tregalizumab (BT-061) in Patients with Rheumatoid Arthritis". Dreieich.

Region Region EUR(WEST)+AM(NORTH)
Organisation Organisation Biotest AG
  Group Creat (Group)
Products Product tregalizumab (BT-061)
  Product 2 clinical research
Person Person Schulz, Gregor (Biotest 201212 CEO)

- Biotest's largest and most complex clinical study is running according to plan

- Patient recruitment completed. More than 300 patients enrolled within the past ten months

Biotest is pleased to announce that the last patient has been included into the Phase IIb study assessing the efficacy and safety of tregalizumab (BT-061) in patients with moderate to severe rheumatoid arthritis. The Phase IIb study also known as TREAT 2b (T cell REgulating Arthritis Trial 2b) is the largest and most complex Biotest study to date. The trial is currently underway in 14 countries and more than 80 study centres in Eastern and Western Europe, the USA, Canada and Mexico. Treatment of patients in the TREAT 2b study continues as planned. Therefore the study is on track and Biotest expects, that the assessment of the endpoints of the study is achieved end of 1st quarter 2015 with top-line results to be reported in the 2nd quarter 2015.

TREAT 2b study is a double blind, randomised and placebo-controlled trial with four treatment groups, evaluating the efficacy and safety of tregalizumab

(BT-061) in patients with rheumatoid arthritis. In the active treatment groups and the main part of the study tregalizumab (BT-061) is administered at doses of 25, 100 and 200 mg subcutaneously once-weekly for a treatment duration of 24 weeks given in combination with methotrexate. Patients in the control arm receive methotrexate only. In patients who respond to treatment, the therapy can be extended for further six months in an 'extension phase'. More information can be found on (identifier NCT 01999192).

"Biotest is committed to develop and market new medications in areas of high medical need. The unique mode of action of BT-061 will hopefully open a new therapeutic option for patients with rheumatoid arthritis and other autoimmune diseases with high efficacy and good quality of life. This new drug is developed in close cooperation with medical and scientific key opinion leaders worldwide," said Prof Gregor Schulz, CEO of Biotest AG. Key data from the main part of TREAT 2b will be the basis for start of Phase III clinical development.

About Tregalizumab (BT-061)

Tregalizumab (BT-061) is a humanized monoclonal anti-CD4 antibody, which selectively activates regulatory T cells (Tregs). Tregalizumab (BT-061) thereby strengthens a natural function of the body that prevents excessive immune reactions. The antibody is being developed to treat diseases due to an overreaction of the immune system such as autoimmune diseases. Tregalizumab (BT-061) is currently in Phase IIb clinical development for rheumatoid arthritis.

About rheumatoid arthritis

Rheumatoid arthritis (RA) is a progressive inflammatory autoimmune disease that affects joints and organs. It is estimated that about 5 million people worldwide suffer from RA, with between 0.3 % and 1 % of the population of industrialized countries affected. The disease occurs three times more often in women than in men. Although RA can affect people of all age groups, the disease in most cases occurs between the ages of 40 and 60 years. Traditional treatment methods against rheumatoid arthritis include nonsteroidal anti-inflammatory drugs (NSAIDs), corticosteroids and disease-modifying antirheumatic drugs (DMARDs). Treatments based on biotechnology preparations have been added recently.


This document contains forward-looking statements on overall economic development as well as on the business, earnings, financial and assets position of Biotest AG and its subsidiaries. These statements are based on current plans, estimates, forecasts and expectations of the company and are thus subject to risks and elements of uncertainty that could result in significant deviation of actual developments from expected developments. The forward-looking statements are only valid at the time of publication. Biotest does not intend to update the forward-looking statements and assumes no obligation to do so.

About Biotest

Biotest is a provider of plasma proteins and biological drugs. With a value added chain that extends from pre-clinical and clinical development to worldwide sales, Biotest has specialised primarily in the areas of clinical immunology, haematology and intensive medicine. Biotest develops and markets immunoglobulins, coagulation factors and albumins based on human blood plasma. These are used for diseases of the immune and haematopoietic systems. In addition Biotest develops monoclonal antibodies in the indications of rheumatoid arthritis and cancer of plasma cells, which are produced by recombinant technologies. Biotest has more than 2.000 employees worldwide. The preference shares of Biotest AG are listed in the SDAX on the Frankfurt stock exchange.

Biotest AG, Landsteinerstr. 5, 63303 Dreieich,
Dr. Monika Buttkereit
tel.: +49 (0) 6103 801-4406,
fax: +49 (0) 6103 801-347

Securities' ID No., ISIN ordinary shares: 522720, DE0005227201
Securities' ID No., ISIN preference shares: 522723, DE0005227235
Listing: Prime Standard
Open Market: Berlin-Bremen, Düsseldorf, Frankfurt, Hamburg, Hanover, Munich, Stuttgart

Record changed: 2019-04-26


Picture [LSUS] – The Business Web Portal 650x65px

More documents for Creat (Group)

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to and simply fill the subject line with the word »LSE Newsletter«

To get even more information, please take a look at our [gs] professional services offering and read the gene-sensor Product Flyer [PDF file]


Picture [LSA] – The Business Web Portal 650x89px

» top